News & Updates
Showing Multidisciplinary articles
Showing

Nonchemotherapy doublet shows therapeutic potential in PD-1/PD-L1 inhibitor‒resistant NSCLC
Combination treatment with eftilagimod alpha plus pembrolizumab has shown promising signal of activity against metastatic nonsmall cell lung cancer (NSCLC) in patients resistant to PD-1/PD-L1 inhibitors, as shown in the updated results of the phase II TACTI-002 study.

New HF criteria set sizeable shift of individuals from stage A to B
The new standards for heart failure (HF) staging proposed in the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) clinical practice guideline has led to a considerable change among community-based individuals from stage A to B.

Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.





